Abstract
Uncertainty surrounding the risk and reward of investments in biopharmaceutical companies poses a challenge to those interested in funding such enterprises. Using data on publicly traded stocks, we track the performance of 1,066 biopharmaceutical companies from 1930 to 2015—the most comprehensive financial analysis of this sector to date. Our systematic exploration of methods for distinguishing biotech and pharmaceutical companies yields a dynamic, more accurate classification method. We find that the performance of the biotech sector is highly sensitive to the presence of a few outlier companies, and confirm that nearly all biotech companies are loss-making enterprises, exhibiting high stock volatility. In contrast, since 2000, pharmaceutical companies have become increasingly profitable, with risk-adjusted returns consistently outperforming the market. The performance of all biopharmaceutical companies is subject not only to factors arising from their drug pipelines (idiosyncratic risk), but also from general economic conditions (systematic risk). The risk associated with returns has profound implications both for patterns of investment and for funding innovation in biomedical R&D.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
TEConomy Partners. The Economic Impact of the US Biopharmaceutical Industry: National and State Estimates http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceuticaul-industry-economic-impact.pdf (Washington, DC: Pharmaceutical Research and Manufacturers of America, 2016).
Cortright, J. & Mayer, H. Signs of Life: the Growth of Biotechnology Centers in the US https://www.brookings.edu/wp-content/uploads/2016/06/biotech.pdf (Center on Urban and Metropolitan Policy, The Brookings Institution, 2002).
Golec, J. & Vernon, J.A. Financial risk of the biotech industry versus the pharmaceutical industry. Appl. Health Econ. Health Policy 7, 155–165 (2009).
Cockburn, I. & Lerner, J. The cost of capital for early stage biotechnology ventures. Congressional Briefing http://buchpedersen.com/wp-content/uploads/2016/02/The-Cost-of-Capital-for-Early-Stage-Biotechnology-Ventures_CockburnLerner.pdf (2009).
Finkelstein, S. & Temin, P. Reasonable Rx: Solving the Drug Price Crisis. (FT Press, 2008).
Booth, B. Debunking myths about biotech venture capital. Forbes 22, http://www.forbes.com/sites/brucebooth/2013/05/22/debunking-myths-about-biotech-venture-capital/ (2013).
Howard, D.H., Bach, P.B., Berndt, E.R. & Conti, R.M. Pricing in the market for anticancer drugs. J. Econ. Perspect. 29, 139–162 (2015).
Fama, E.F. & French, K.R. Disappearing dividends: changing firm characteristics or lower propensity to pay? J. Financ. Econ. 60, 3–43 (2001).
Thakor, R.T. & Lo, A.W. Competition and R&D financing decisions: evidence from the biopharmaceutical industry. Working Paper, MIT Sloan School of Management, 2016.
Koijen, R.S.J., Philipson, T.J. & Uhlig, H. Financial health economics. Econometrica 84, 195–242 (2016).
Myers, S.C. & Howe, C.D. A life-cycle financial model of pharmaceutical R&D http://www.worldcat.org/title/life-cycle-financial-model-of-pharmaceutical-r-d/oclc/42739394 Program on the Pharmaceutical Industry, Sloan School of Management, Massachusetts Institute of Technology, 1997.
Myers, S.C. & Shyam-Sunder, L. in Competitive Strategies in the Pharmaceutical Industry, (ed. Helms, R.B. 208–237) (American Enterprise Institute for Public Policy: Washington, DC, 1995).
Lyandres, E. & Palazzo, B. Cash holdings, competition, and innovation. J. Financ. Quant. Anal. 51, 1823–1861 (2016).
Nanda, R. & Rhodes-Kropf, M. Investment cycles and startup innovation. J. Financ. Econ. 110, 403–418 (2013).
Nanda, R. & Rhodes-Kropf, M. Financing risk and innovation. Manage. Sci. 63, 901–918 (2016).
Lerner, J., Shane, H. & Tsai, A. Do equity financing cycles matter? Evidence from biotechnology alliances. J. Financ. Econ. 67, 411–446 (2003).
Rajan, R.G. & Zingales, L. Financial dependence and growth. Am. Econ. Rev. 88, 559–586 (1998).
Brown, J.R., Fazzari, S.M. & Petersen, B.C. Financing innovation and growth: Cash flow, external equity, and the 1990s R&D boom. J. Finance 64, 151–185 (2009).
Kerr, W.R. & Nanda, R. Financing innovation. Annu. Rev. Financ. Econ. 7, 445–462 (2015).
Lo, A.W. & Pisano, G. Lessons From Hollywood: a new approach to funding innovation. Sloan Manage. Rev. 57, 47–57 (2015).
Fagnan, D.E., Fernandez, J.M., Lo, A.W. & Stein, R.M. Can financial engineering cure cancer? Am. Econ. Rev. 103, 406–411 (2013).
Fernandez, J.-M., Stein, R.M. & Lo, A.W. Commercializing biomedical research through securitization techniques. Nat. Biotechnol. 30, 964–975 (2012).
Jørring, A., Lo, A.W., Philipson, T.J., Singh, M. & Thakor, R.T. Sharing R&D risk in healthcare via FDA hedges. No. w23344 http://www.nber.org/papers/w23344 (National Bureau of Economic Research, 2017).
Philipson, T. Hedging pipeline risk in pharma: FDA swaps and annuities https://pdfs.semanticscholar.org/6b84/3c138131fd45f279e51ddd8b2a1c8bc008d3.pdf (Milken Institute, March 2015).
Carlson, R. Estimating the biotech sector's contribution to the US economy. Nat. Biotechnol. 34, 247–255 (2016).
Hoberg, G. & Phillips, G. Text-based network industries and endogenous product differentiation. J. Polit. Econ. 124, 1423–1465 (2016).
Hoberg, G. & Phillips, G. Product market synergies and competition in mergers and acquisitions: A text-based analysis. Rev. Financ. Stud. 23, 3773–3811 (2010).
Acknowledgements
We thank Jayna Cummings for editorial support. Funding support from the MIT Laboratory for Financial Engineering is gratefully acknowledged.
Author information
Authors and Affiliations
Contributions
A.W.L. first conceived of the idea of analyzing the financial risks and return of the biotech and pharmaceutical industries, proposed the basic design of the empirical and statistical analysis, assembled key members of the project team, provided funding through the MIT Laboratory for Financial Engineering, and was responsible for overall project management, manuscript preparation, and journal submission. Initial data collection, data cleaning, and preliminary analysis of company-specific stock returns were performed by N.A., Y.Z., and C.V., and reviewed by A.W.L. and R.T.T. More comprehensive data collection, data cleaning, financial modeling, and detailed analysis of stock returns and accounting data were performed by R.T.T., who was involved in every aspect of the design of the project and the data analysis, with input from A.W.L. All aspects of the financial modeling and data analysis were reviewed by A.W.L. A.W.L. conceived of using an algorithmic approach to perform industrial classification on a rolling-window basis, and K.W.S. and C.H.W. developed the algorithms for classifying companies into biotech and pharma industries with input from and review by R.T.T. and A.W.L. All authors participated in preparing the first draft of the main manuscript, and A.W.L. reviewed and edited this draft to produce the final version. K.W.S. and C.H.W. prepared the initial draft of Supplementary Methods with input from R.T.T. and A.W.L., and R.T.T. and A.W.L. edited this draft to produce the final version. R.T.T. prepared the initial draft of Supplementary Notes and Supplementary Results with input from A.W.L., and A.W.L. edited this draft to produce the final version.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–3, Supplementary Tables 1–6, Supplementary Methods, Supplementary Notes, and Supplementary Results (PDF 1695 kb)
Rights and permissions
About this article
Cite this article
Thakor, R., Anaya, N., Zhang, Y. et al. Just how good an investment is the biopharmaceutical sector?. Nat Biotechnol 35, 1149–1157 (2017). https://doi.org/10.1038/nbt.4023
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4023
This article is cited by
-
A Framework for the Fair Pricing of Medicines
PharmacoEconomics (2024)
-
Volatility spillovers, structural breaks and uncertainty in technology sector markets
Financial Innovation (2023)
-
Systematic risk in the biopharmaceutical sector: a multiscale approach
Annals of Operations Research (2023)
-
Can Financial Economics Cure Cancer?
Atlantic Economic Journal (2021)
-
Stock price reaction to the drug development setbacks in the pharmaceutical industry
DARU Journal of Pharmaceutical Sciences (2021)